Log In
Print
BCIQ
Print
Print this Print this
 

ALN-VSP, ASC-06

Also known as: formerly ALN-VSP01

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNA therapeutic targeting kinesin spindle protein (KSP) and VEGF genes
Molecular Target Vascular endothelial growth factor (VEGF) ; Kinesin spindle protein (KSP) (Eg5) (TRIP5)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationLiver cancer
Indication DetailsTreat advanced liver cancer; Treat hepatocellular carcinoma (HCC); Treat liver cancer
Regulatory Designation

Partner

Ascletis Pharmaceuticals Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today